je.st
news
Tag: advanced
Stocks On the Move: Alcobra Ltd, Deckers Outdoor Corp, and GT Advanced Technologies Inc
2014-10-07 17:07:09| Footwear - Topix.net
Earlier, in fact, the stock hit a record low of $6.16, and landed on the short-sale restricted list. These developments are likely music to the ears of short sellers .
Tags: inc
advanced
move
outdoor
DOE issues draft loan guarantee solicitation for up to $12.6B for advanced nuclear energy projects
2014-09-30 20:31:01| Green Car Congress
Tags: advanced
issues
energy
projects
Microsemi Expands Customer Application Design Opportunities By Introducing SmartFusion2 Advanced Development Kit With Largest Density 150K LE Device
2014-09-30 13:13:07| wirelessdesignonline News Articles
Microsemi Corporation (Nasdaq: MSCC), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance, today announced the availability of the company's new largest density, lowest power SmartFusion®2 150K LE System-on-Chip (SoC) FPGA Advanced Development Kit.
Tags: advanced
design
development
customer
Advanced Atomization Technologies Announces Distribution and Maintenance Worldwide Network for Land and Marine Fuel Nozzles
2014-09-29 16:57:00| Power Technology
Advanced Atomization Technologies (AA TECH), a joint venture between Parker Aerospace and GE Aviation, has established a worldwide distribution and maintenance network for the fuel nozzles used on GE land and marine engine platforms.
Tags: advanced
network
land
distribution
Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014
2014-09-29 11:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
data
advanced
early
Sites : [270] [271] [272] [273] [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] next »